As part of the deal, both the firms will carry out collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Eisai’s choice, to develop new pharmaceutical products primarily for diseases of the central nervous system (CNS).
The J-Brain Cargo technology allows delivery of target substances across the BBB through a certain receptor expressed on the surface of vascular endothelial cells.
According to JCR, the studies carried out by them confirmed BBB penetration of J-Brain Cargo combined target substance as 20 to 100 times the target substance alone.
J-Brain Cargo provides pharmaceutical compounds of small or large molecules with the capacity to pass through the BBB, while a substantially large portion of the pharmaceutical injected intravenously should be able to reach inside the brain and confer its effect.
The company noted that significant improvements are expected for neurological disorders for which little improvements have been possible.
JCR is focused on the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine for the treatment of rare diseases.
Image: Eisai head office in Tokyo, Japan. Photo: courtesy of Arthena.